Over the course of evolution, the genomes of most living organisms have grown more complex thanks to transposable elements, a.k.a. “jumping genes,” or DNA fragments that can move and copy themselves from one chromosome location to another. Researchers from Inserm, the CNRS, Université Côte d’Azur, and Université de Montpellier were able to capture these “jumping genes” just after they moved.
Today, around 1 in 8 couples seek help because they are struggling to conceive. Infertility has therefore become a public health problem, and the scientific community is rallying in response.
A novel IT tool based on artificial intelligence methods has made it possible to identify the toxic effects of bisphenol S – a frequent substitute for bisphenol A in food containers.
Une équipe de chercheurs est parvenue à estimer le nombre de nouveaux cas et le coût économique direct que représentent les infections à bactéries résistantes aux antibiotiques chez les malades hospitalisés, pendant les années 2015 et 2016.
Firibastat is the first in a new class of antihypertensive drugs targeting the renin-angiotensin system in the brain.
ChroMS is a new microscopy technique bringing together color, 3D and high-resolution imaging, and is nothing short of a revolution in vertebrate brain imaging.
The team of Béhazine Combadière, Inserm Research Director at Unit 1135 "Center for Immunology and Infectious Diseases", has been working for years on the impact of vaccine administration routes on the quality of immune responses.
Cesarean delivery is thought to be linked to a greater risk of severe maternal complications – primarily hemorrhagic - than vaginal delivery, especially in women aged 35 and over.
How can the quality of life of patients with narcolepsy, the severest sleep disorder in humans, be improved? An international scientific team led by Yves Dauvilliers, a researcher at Inserm and Université de Montpellier, is working on Solriamfetol – a promising new drug that stimulates alertness and improves resistance to sleepiness.
Researchers are now able to edit the genome with precision using the "gene editing scissors" of CRISPR-Cas9, which is a highly promising tool for gene therapy. The technical challenge now is to get this tool into the genome of certain cells. With this in mind, a joint team from Inserm, the CNRS, the Université Claude Bernard Lyon 1, and the École Normale Supérieure de Lyon, working within the International...